Endurance Bio Inc.

Endurance Bio Inc. develops orally bioavailable small molecules T-168 (phase 2) and T-621 (nonclinical development) that upregulate PGC-1α, which boosts mitochondrial health and, through direct and indirect mechanisms, upregulates TFEB and TRPML1, leading to improved lysosomal function and cellular homeostasis. This mechanism is responsible for enhanced mitochondrial biogenesis, metabolic gene upregulation, lysosomal biogenesis, lysosomal acidification and enhanced autophagy. In studies executed by Endurance Bio and collaborators, upregulation of PGC-1α, TFEB and TRPML1 has demonstrated therapeutic promise in preclinical models of neurodegeneration, inflammation, and aging. In addition, published in vivo and in vitro research suggests that this approach may also have potential benefits in a neurological conditions beyond neurodegeneration such as autism, as well as a variety of metabolic, cardiovascular, blood, liver, kidney, and muscle disorders. Endurance Bio’s development plan includes a placebo-controlled phase 2 trial of T-168 in Parkinson’s disease. This trial is expected to start in the second half of 2025. In addition, Endurance Bio has an approved CTA to commence a clinical phase 2 trial in ALS. The initiation of this study requires additional funding which Endurance Bio is currently pursuing. Lastly, Endurance Bio’s business plan includes several animal pharmacology studies and IND enabling studies with T-621 in a variety of diseases. Endurance Bio is open to T-168 and T-621 partnering (i.e. option or licensing) deals across different disease areas and indications in human and animal health.